In this interview we discuss preliminary results of the COMPASS trial, which used whole-genome sequencing and RNA sequencing to analyze the tumors of patients with advanced pancreatic ductal adenocarcinoma to identify possible first-line treatments.
Kyaw L. Aung, MBBS, PhD
Advertisement
Articles by Kyaw L. Aung, MBBS, PhD
Advertisement
Latest Updated Articles
COMPASS: Genomic Profiling Could Guide Treatment in Advanced Pancreatic CancerPublished: February 2nd 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
2
Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC
3
ASCENT-03 Trial Supports Standard Use of Sacituzumab Govitecan in mTNBC
4
TUB-040 Elicits Early Responses in Platinum-Resistant Ovarian Cancer
5
